{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Error analysis for the type of examples that NER blinding get wrong compared to the baseline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "%autoreload\n",
    "import os\n",
    "from sys import path\n",
    "import re\n",
    "import pandas as pd\n",
    "path.append('../../..')\n",
    "import numpy as np\n",
    "from scipy.stats import ttest_rel\n",
    "from relation_extraction.data.converters.converter_ddi import relation_dict\n",
    "output_path = '/scratch/geeticka/relation-extraction-result/ddi-analyze/'\n",
    "def res(path): return os.path.join(output_path, path)\n",
    "original_sentences_path = os.path.join('/scratch/geeticka/relation-extraction-result/ddi-analyze/test_original.txt')\n",
    "ner_blinding_sentences_path = os.path.join('/crimea/geeticka/data/relation_extraction/ddi/pre-processed/ner_blinding/test_ner_blinding.txt')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{0: 'advise', 1: 'effect', 2: 'mechanism', 3: 'int', 4: 'none'}"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "relation_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_answers_line(line):\n",
    "    linenum, relation = line.strip().split()\n",
    "    return linenum, relation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "def asstring(list_of_strings):\n",
    "    return \" \".join(list_of_strings)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "def read_sentence_and_entities(line):\n",
    "    line = line.strip().split()\n",
    "    sentence = line[5:]\n",
    "    relation = relation_dict[int(line[0])]\n",
    "    entity1_idx = (int(line[1]), int(line[2]))\n",
    "    entity2_idx = (int(line[3]), int(line[4]))\n",
    "    entity1 = sentence[entity1_idx[0] : entity1_idx[1] + 1]\n",
    "    entity2 = sentence[entity2_idx[0] : entity2_idx[1] + 1]\n",
    "    \n",
    "    return relation, asstring(entity1), asstring(entity2), asstring(sentence)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "needed_linenum_and_relation = {}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(res(\"answers_for_dev-ner-blinding.txt\")) as textfile1, open(res('answers_for_dev-baseline.txt')) as textfile2, \\\n",
    "open(res('answers_for_dev-baseline_gold.txt')) as textfile3: \n",
    "    for x, y, z in zip(textfile1, textfile2, textfile3):\n",
    "        linenum, ner_blinding_relation = read_answers_line(x)\n",
    "        _, baseline_relation = read_answers_line(y)\n",
    "        _, gold_relation = read_answers_line(z)\n",
    "        if baseline_relation == gold_relation and ner_blinding_relation != gold_relation: # punct digit making mistakes\n",
    "            needed_linenum_and_relation[int(linenum) - 1] = (baseline_relation, ner_blinding_relation)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "311"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list(needed_linenum_and_relation.keys()))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "6.622657580919931"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(list(needed_linenum_and_relation.keys()))/len(open(res('answers_for_dev-baseline_gold.txt')).readlines()) * 100"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Remember that baseline is correct here so the first relation listed is the correct one, unlike in the i2b2 notebook where the order is reversed because baseline is the incorrect one there"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "entities_blinded_per_sentence = []\n",
    "interaction = 0; mechanism = 0; advice = 0; effect = 0; none = 0"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "We print the baseline first and then the ner blinded version. Gold relation corresponds to baseline\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Terbinafine, ENTITY \t cimetidine, ENTITY \n",
      "Sentences: \n",
      "\tTerbinafine clearance is increased 100 % by rifampin , a CyP450 enzyme inducer , and decreased 33 % by cimetidine , a CyP450 enzyme inhibitor . \n",
      "\t ENTITY ENTITY is ENTITY 100 % by ENTITY , a ENTITY ENTITY , and ENTITY 33 % by ENTITY , a ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t gemfibrozil, ENTITY \t rifampin, ENTITY \n",
      "Sentences: \n",
      "\tAn inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of rosiglitazone . \n",
      "\t An ENTITY of ENTITY ( such as ENTITY ) may ENTITY the ENTITY of ENTITY and an ENTITY of ENTITY ( such as ENTITY ) may ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t gemfibrozil, ENTITY \t rosiglitazone, ENTITY \n",
      "Sentences: \n",
      "\tAn inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of rosiglitazone . \n",
      "\t An ENTITY of ENTITY ( such as ENTITY ) may ENTITY the ENTITY of ENTITY and an ENTITY of ENTITY ( such as ENTITY ) may ENTITY the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t rosiglitazone, ENTITY \t rosiglitazone, ENTITY \n",
      "Sentences: \n",
      "\tAn inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of rosiglitazone . \n",
      "\t An ENTITY of ENTITY ( such as ENTITY ) may ENTITY the ENTITY of ENTITY and an ENTITY of ENTITY ( such as ENTITY ) may ENTITY the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t rifampin, ENTITY \t rosiglitazone, ENTITY \n",
      "Sentences: \n",
      "\tAn inhibitor of CYP2C8 ( such as gemfibrozil ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 ( such as rifampin ) may decrease the AUC of rosiglitazone . \n",
      "\t An ENTITY of ENTITY ( such as ENTITY ) may ENTITY the ENTITY of ENTITY and an ENTITY of ENTITY ( such as ENTITY ) may ENTITY the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t coumarin anticoagulants, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t anticonvulsants, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t phenobarbital, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t diphenylhydantoin, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t primidone, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t phenylbutazone, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t tricyclic drugs, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t imipramine, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t clomipramine, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Ritalin, ENTITY \t desipramine, ENTITY \n",
      "Sentences: \n",
      "\tHuman pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) . \n",
      "\t ENTITY ENTITY have shown that ENTITY may ENTITY the ENTITY of ENTITY , ENTITY ( ENTITY , ENTITY , ENTITY ) , ENTITY , and ENTITY ( ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t methylphenidate, ENTITY \t clonidine, ENTITY \n",
      "Sentences: \n",
      "\tThe safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated . \n",
      "\t The ENTITY of using ENTITY in ENTITY with ENTITY or other ENTITY alpha-2 ENTITY has not been ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Trimethoprim, ENTITY \t phenytoin, ENTITY \n",
      "Sentences: \n",
      "\tTrimethoprim may inhibit the hepatic metabolism of phenytoin . \n",
      "\t ENTITY may ENTITY the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Trimethoprim, ENTITY \t phenytoin, ENTITY \n",
      "Sentences: \n",
      "\tTrimethoprim , given at a common clinical dosage , increased the phenytoin half - life by 51 % and decreased the phenytoin metabolic clearance rate by 30 % . \n",
      "\t ENTITY , given at a common ENTITY , ENTITY the ENTITY ENTITY - ENTITY by 51 % and ENTITY the ENTITY ENTITY ENTITY ENTITY by 30 % .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t phenytoin, ENTITY \t phenytoin, ENTITY \n",
      "Sentences: \n",
      "\tTrimethoprim , given at a common clinical dosage , increased the phenytoin half - life by 51 % and decreased the phenytoin metabolic clearance rate by 30 % . \n",
      "\t ENTITY , given at a common ENTITY , ENTITY the ENTITY ENTITY - ENTITY by 51 % and ENTITY the ENTITY ENTITY ENTITY ENTITY by 30 % .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t aspirin, ENTITY \t heparin, ENTITY \n",
      "Sentences: \n",
      "\tAGGRASTAT has been studied on a background of aspirin and heparin . \n",
      "\t ENTITY has been studied on a ENTITY of ENTITY and ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t AGGRASTAT, ENTITY \t aspirin, ENTITY \n",
      "Sentences: \n",
      "\tThe use of AGGRASTAT , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see \n",
      "\t The use of ENTITY , in ENTITY with ENTITY and ENTITY , has been ENTITY an ENTITY in ENTITY compared to ENTITY and ENTITY alone ( see\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenytoin, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tWhen phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . \n",
      "\t When ENTITY or other ENTITY ENTITY such as ENTITY and ENTITY have been taken concurrently with ENTITY , ENTITY ENTITY levels have been reported .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t rifampin, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tWhen phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . \n",
      "\t When ENTITY or other ENTITY ENTITY such as ENTITY and ENTITY have been taken concurrently with ENTITY , ENTITY ENTITY levels have been reported .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenobarbital, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tWhen phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported . \n",
      "\t When ENTITY or other ENTITY ENTITY such as ENTITY and ENTITY have been taken concurrently with ENTITY , ENTITY ENTITY levels have been reported .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Mexitil, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tConcurrent administration of cimetidine and Mexitil has been reported to increase , decrease , or leave unchanged Mexitil plasma levels ; \n",
      "\t ENTITY ENTITY of ENTITY and ENTITY has been reported to ENTITY , ENTITY , or leave ENTITY ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Mexitil, ENTITY \t theophylline, ENTITY \n",
      "Sentences: \n",
      "\tConcurrent use of Mexitil and theophylline may lead to increased plasma theophylline levels . \n",
      "\t ENTITY ENTITY ENTITY and ENTITY may lead to ENTITY ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Mexitil, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Mexitil, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Theophylline, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Theophylline, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Theophylline, ENTITY \t theophylline, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Mexitil, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Mexitil, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Mexitil, ENTITY \t theophylline, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Mexitil, ENTITY \t theophylline, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Mexitil, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Mexitil, ENTITY \t theophylline, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Mexitil, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t theophylline, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tThis increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the Mexitil dose is changed . \n",
      "\t This ENTITY was observed at the first test point which was the second ENTITY after starting ENTITY . ENTITY ENTITY levels returned to pre- ENTITY within 48 hours after ENTITY ENTITY . If ENTITY and ENTITY are to be used concurrently , ENTITY ENTITY should be ENTITY , particularly when the ENTITY is changed .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t caffeine, ENTITY \t Mexitil, ENTITY \n",
      "Sentences: \n",
      "\tAdditionally , in one controlled study in five normal subjects and seven patients , the clearance of caffeine was decreased 50 % following the administration of Mexitil . \n",
      "\t Additionally , in one ENTITY in five ENTITY and seven ENTITY , the ENTITY of ENTITY was ENTITY 50 % following the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t GH, ENTITY \t corticosteroids, ENTITY \n",
      "Sentences: \n",
      "\tThese data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) . \n",
      "\t These ENTITY suggest that ENTITY may alter the ENTITY of ENTITY known to be ENTITY by ENTITY ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t GH, ENTITY \t cyclosporin, ENTITY \n",
      "Sentences: \n",
      "\tThese data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) . \n",
      "\t These ENTITY suggest that ENTITY may alter the ENTITY of ENTITY known to be ENTITY by ENTITY ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Anticoagulants, ENTITY \t methimazole, ENTITY \n",
      "Sentences: \n",
      "\tAnticoagulants ( oral ) : The activity of oral anticoagulants may be potentiated by anti - vitamin - K activity attributed to methimazole . \n",
      "\t ENTITY ( ENTITY ) : The ENTITY of ENTITY may be ENTITY by ENTITY - ENTITY - ENTITY ENTITY attributed to ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Theophylline, ENTITY \t theophylline, ENTITY \n",
      "Sentences: \n",
      "\tTheophylline : Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid ; \n",
      "\t ENTITY : ENTITY ENTITY may ENTITY when ENTITY ENTITY on a stable ENTITY ENTITY become ENTITY ;\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t opioids, ENTITY \t droperidol, ENTITY \n",
      "Sentences: \n",
      "\tand combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) . \n",
      "\t and ENTITY of ENTITY and ENTITY ( eg , ENTITY , ENTITY , ENTITY , ENTITY , etc . ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t anticoagulant, ENTITY \t warfarin, ENTITY \n",
      "Sentences: \n",
      "\tIt has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin . \n",
      "\t It has been reported that ENTITY may ENTITY the ENTITY in ENTITY who are receiving the ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Sulfamethoxazole, ENTITY \t phenytoin, ENTITY \n",
      "Sentences: \n",
      "\tSulfamethoxazole may inhibit the hepatic metabolism of phenytoin . \n",
      "\t ENTITY may ENTITY the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Sulfonamides, ENTITY \t methotrexate, ENTITY \n",
      "Sentences: \n",
      "\tSulfonamides can also displace methotrexate from plasma protein - binding sites , thus increasing free methotrexate concentrations . \n",
      "\t ENTITY can also displace ENTITY from ENTITY - ENTITY , thus increasing ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Posicor, ENTITY \t astemizole, ENTITY \n",
      "Sentences: \n",
      "\tPosicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . \n",
      "\t ENTITY ENTITY some of the ENTITY ability to ENTITY some other ENTITY - ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Posicor, ENTITY \t cisapride, ENTITY \n",
      "Sentences: \n",
      "\tPosicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . \n",
      "\t ENTITY ENTITY some of the ENTITY ability to ENTITY some other ENTITY - ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Posicor, ENTITY \t cyclosporine, ENTITY \n",
      "Sentences: \n",
      "\tPosicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . \n",
      "\t ENTITY ENTITY some of the ENTITY ability to ENTITY some other ENTITY - ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Posicor, ENTITY \t tricyclic antidepressants, ENTITY \n",
      "Sentences: \n",
      "\tPosicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants . \n",
      "\t ENTITY ENTITY some of the ENTITY ability to ENTITY some other ENTITY - ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, advise \n",
      "Entities: \t Sanctura, ENTITY \t anticholinergic agents, ENTITY \n",
      "Sentences: \n",
      "\tThe concomitant use of Sanctura with other anticholinergic agents that produce dry mouth , constipation , and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects . \n",
      "\t The ENTITY use of ENTITY with other ENTITY that produce ENTITY , ENTITY , and other ENTITY ENTITY may ENTITY the ENTITY and/or ENTITY of such ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Sanctura, ENTITY \t digoxin, ENTITY \n",
      "Sentences: \n",
      "\tDrugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . \n",
      "\t ENTITY ENTITY by ENTITY ENTITY : Although ENTITY to ENTITY ENTITY - ENTITY with ENTITY have not been conducted , ENTITY has the ENTITY for ENTITY with other ENTITY that are eliminated by ENTITY ( e.g. ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY and ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Sanctura, ENTITY \t tenofovir, ENTITY \n",
      "Sentences: \n",
      "\tDrugs Eliminated by Active Tubular Secretion : Although studies to assess drug - drug interactions with Sanctura have not been conducted , Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) . \n",
      "\t ENTITY ENTITY by ENTITY ENTITY : Although ENTITY to ENTITY ENTITY - ENTITY with ENTITY have not been conducted , ENTITY has the ENTITY for ENTITY with other ENTITY that are eliminated by ENTITY ( e.g. ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY and ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t corticosteroids, ENTITY \t bacitracin, ENTITY \n",
      "Sentences: \n",
      "\tSome drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants \n",
      "\t Some ENTITY are : - ENTITY ENTITY - ENTITY - ENTITY for ENTITY or ENTITY - ENTITY for ENTITY - ENTITY to ENTITY such as ENTITY or ENTITY - ENTITY ENTITY given by ENTITY - ENTITY - ENTITY - ENTITY - ENTITY or ENTITY - ENTITY ENTITY such as ENTITY - ENTITY ENTITY - ENTITY or other ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t corticosteroids, ENTITY \t anesthetics, ENTITY \n",
      "Sentences: \n",
      "\tSome drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants \n",
      "\t Some ENTITY are : - ENTITY ENTITY - ENTITY - ENTITY for ENTITY or ENTITY - ENTITY for ENTITY - ENTITY to ENTITY such as ENTITY or ENTITY - ENTITY ENTITY given by ENTITY - ENTITY - ENTITY - ENTITY - ENTITY or ENTITY - ENTITY ENTITY such as ENTITY - ENTITY ENTITY - ENTITY or other ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t Metopirone, ENTITY \t acetaminophen, ENTITY \n",
      "Sentences: \n",
      "\tMetopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity . \n",
      "\t ENTITY ENTITY the ENTITY of ENTITY and could possibly ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Pyrimethamine, ENTITY \t quinine, ENTITY \n",
      "Sentences: \n",
      "\tPyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . \n",
      "\t ENTITY may be used with ENTITY , ENTITY and other ENTITY , and with other ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t Pyrimethamine, ENTITY \t antimalarials, ENTITY \n",
      "Sentences: \n",
      "\tPyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics . \n",
      "\t ENTITY may be used with ENTITY , ENTITY and other ENTITY , and with other ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Streptase, ENTITY \t antiplatelet agents, ENTITY \n",
      "Sentences: \n",
      "\tUse of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . \n",
      "\t Use of ENTITY and ENTITY -- ENTITY , ENTITY , alone or in ENTITY with ENTITY and ENTITY , may cause ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Streptase, ENTITY \t anticoagulants, ENTITY \n",
      "Sentences: \n",
      "\tUse of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . \n",
      "\t Use of ENTITY and ENTITY -- ENTITY , ENTITY , alone or in ENTITY with ENTITY and ENTITY , may cause ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Streptokinase, ENTITY \t antiplatelet agents, ENTITY \n",
      "Sentences: \n",
      "\tUse of Anticoagulants and Antiplatelet Agents -- Streptase , Streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications . \n",
      "\t Use of ENTITY and ENTITY -- ENTITY , ENTITY , alone or in ENTITY with ENTITY and ENTITY , may cause ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t aspirin, ENTITY \t Streptokinase, ENTITY \n",
      "Sentences: \n",
      "\tThe addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding ( 3.9 % vs. 3.1 % ) , but does not appear to increase the incidence of major bleeding ( see \n",
      "\t The addition of ENTITY to ENTITY causes a minimal ENTITY in the ENTITY of ENTITY ( 3.9 % vs. 3.1 % ) , but does not appear to ENTITY the ENTITY of ENTITY ( see\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Nalidixic acid, ENTITY \t melphalan, ENTITY \n",
      "Sentences: \n",
      "\tDRUG INTERACTIONS There are no known drug / drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high - dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis . \n",
      "\t ENTITY ENTITY There are no known ENTITY / ENTITY with ENTITY ENTITY with ENTITY ENTITY are not recommended in ENTITY ENTITY ENTITY together with ENTITY - ENTITY ENTITY has caused ENTITY in ENTITY due to ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t melphalan, ENTITY \t cyclosporin, ENTITY \n",
      "Sentences: \n",
      "\tImpaired renal function has been described in bone marrow transplant patients who were conditioned with high - dose intravenous melphalan and who subsequently received cyclosporin to prevent graft - versus - host disease \n",
      "\t ENTITY ENTITY has been described in ENTITY ENTITY who were ENTITY with ENTITY - ENTITY ENTITY and who subsequently received ENTITY to ENTITY ENTITY - ENTITY - ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t cyclosporine, ENTITY \t cyclosporine, ENTITY \n",
      "Sentences: \n",
      "\tCyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . \n",
      "\t ENTITY : ENTITY from a ENTITY and ENTITY indicate a ENTITY in ENTITY ENTITY levels when ENTITY was ENTITY with ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t cyclosporine, ENTITY \t cyclosporine, ENTITY \n",
      "Sentences: \n",
      "\tCyclosporine : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine . \n",
      "\t ENTITY : ENTITY from a ENTITY and ENTITY indicate a ENTITY in ENTITY ENTITY levels when ENTITY was ENTITY with ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, none \n",
      "Entities: \t Trilostane, ENTITY \t aminoglutethimide, ENTITY \n",
      "Sentences: \n",
      "\tTrilostane may interact with aminoglutethimide or mitotane ( causing too great a decrease in adrenal function ) . \n",
      "\t ENTITY may ENTITY with ENTITY or ENTITY ( causing too great a ENTITY in ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Ropivacaine, ENTITY \t ropivacaine, ENTITY \n",
      "Sentences: \n",
      "\tThus strong inhibitors of cytochrome P4501A2 , such as fluvoxamine , given concomitantly during administration of Ropivacaine , can interact with Ropivacaine leading to increased ropivacaine plasma levels . \n",
      "\t Thus strong ENTITY of ENTITY , such as ENTITY , given concomitantly during ENTITY of ENTITY , can ENTITY with ENTITY leading to ENTITY ENTITY ENTITY levels .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t Zidovudine, ENTITY \t stavudine, ENTITY \n",
      "Sentences: \n",
      "\tZidovudine competitively inhibits the intracellular phosphorylation of stavudine . \n",
      "\t ENTITY ENTITY ENTITY the ENTITY ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t paclitaxel, ENTITY \t HERCEPTIN, ENTITY \n",
      "Sentences: \n",
      "\tAdministration of paclitaxel in combination with HERCEPTIN resulted in a two - fold decrease in HERCEPTIN clearance in a non - human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies . \n",
      "\t ENTITY of ENTITY in ENTITY with ENTITY resulted in a two - ENTITY ENTITY in ENTITY ENTITY in a ENTITY - ENTITY ENTITY ENTITY and in a 1.5-fold ENTITY in ENTITY ENTITY in ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t vigabatrin, ENTITY \t phenytoin, ENTITY \n",
      "Sentences: \n",
      "\tIn 1984 , Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment - resistant epilepsy . \n",
      "\t In 1984 , ENTITY and ENTITY at the ENTITY reported that ENTITY ENTITY with ENTITY ENTITY the ENTITY ENTITY ENTITY in ENTITY with ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ZEMURON, ENTITY \t succinylcholine, ENTITY \n",
      "Sentences: \n",
      "\tThe median duration of action of ZEMURON 0.6 mg / kg administered after a 1 mg / kg dose of succinylcholine when T 1 returned to 75 % of control was 36 minutes ( range 14 - 57 , n=12 ) vs. \n",
      "\t The ENTITY ENTITY of ENTITY of ENTITY 0.6 mg / kg ENTITY after a 1 mg / kg ENTITY of ENTITY when ENTITY returned to 75 % of ENTITY was 36 ENTITY ( range 14 - 57 , n=12 ) vs.\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t ZEMURON, ENTITY \t nondepolarizing muscle relaxants, ENTITY ENTITY \n",
      "Sentences: \n",
      "\tThere are no controlled studies documenting the use of ZEMURON before or after other nondepolarizing muscle relaxants . \n",
      "\t There are ENTITY documenting the use of ENTITY before or after other ENTITY ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t FELDENE, ENTITY \t coumarin - type anticoagulants, ENTITY - ENTITY ENTITY \n",
      "Sentences: \n",
      "\tAlthough this has not occurred in in vitro studies with coumarin - type anticoagulants , interactions with coumarin - type anticoagulants have been reported with FELDENE since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin - type anticoagulants and other highly protein - bound drugs . \n",
      "\t Although this has not occurred in ENTITY with ENTITY - ENTITY , ENTITY with ENTITY - ENTITY have been reported with ENTITY since ENTITY , therefore , ENTITY should closely monitor ENTITY for a ENTITY in ENTITY ENTITY when ENTITY ENTITY to ENTITY on ENTITY - ENTITY ENTITY and other highly ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t piroxicam, ENTITY \t FELDENE, ENTITY \n",
      "Sentences: \n",
      "\tPlasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . \n",
      "\t ENTITY ENTITY of ENTITY are ENTITY to ENTITY 80 % of their ENTITY when ENTITY is ENTITY in ENTITY with ENTITY ( 3900 mg / ENTITY ) , but ENTITY ENTITY of ENTITY has ENTITY on ENTITY ENTITY levels . ENTITY - ENTITY , including ENTITY , have been reported to ENTITY ENTITY ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t piroxicam, ENTITY \t antacids, ENTITY \n",
      "Sentences: \n",
      "\tPlasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . \n",
      "\t ENTITY ENTITY of ENTITY are ENTITY to ENTITY 80 % of their ENTITY when ENTITY is ENTITY in ENTITY with ENTITY ( 3900 mg / ENTITY ) , but ENTITY ENTITY of ENTITY has ENTITY on ENTITY ENTITY levels . ENTITY - ENTITY , including ENTITY , have been reported to ENTITY ENTITY ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t piroxicam, ENTITY \t lithium, ENTITY \n",
      "Sentences: \n",
      "\tPlasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . \n",
      "\t ENTITY ENTITY of ENTITY are ENTITY to ENTITY 80 % of their ENTITY when ENTITY is ENTITY in ENTITY with ENTITY ( 3900 mg / ENTITY ) , but ENTITY ENTITY of ENTITY has ENTITY on ENTITY ENTITY levels . ENTITY - ENTITY , including ENTITY , have been reported to ENTITY ENTITY ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t FELDENE, ENTITY \t antacids, ENTITY \n",
      "Sentences: \n",
      "\tPlasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . \n",
      "\t ENTITY ENTITY of ENTITY are ENTITY to ENTITY 80 % of their ENTITY when ENTITY is ENTITY in ENTITY with ENTITY ( 3900 mg / ENTITY ) , but ENTITY ENTITY of ENTITY has ENTITY on ENTITY ENTITY levels . ENTITY - ENTITY , including ENTITY , have been reported to ENTITY ENTITY ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t FELDENE, ENTITY \t FELDENE, ENTITY \n",
      "Sentences: \n",
      "\tPlasma levels of piroxicam are depressed to approximately 80 % of their normal values when FELDENE is administered in conjunction with aspirin ( 3900 mg / day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti - inflammatory agents , including FELDENE , have been reported to increase steady state plasma lithium levels . \n",
      "\t ENTITY ENTITY of ENTITY are ENTITY to ENTITY 80 % of their ENTITY when ENTITY is ENTITY in ENTITY with ENTITY ( 3900 mg / ENTITY ) , but ENTITY ENTITY of ENTITY has ENTITY on ENTITY ENTITY levels . ENTITY - ENTITY , including ENTITY , have been reported to ENTITY ENTITY ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t paliperidone, ENTITY \t centrally acting drugs, ENTITY \n",
      "Sentences: \n",
      "\tGiven the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other centrally acting drugs and alcohol . \n",
      "\t Given the ENTITY ENTITY ENTITY of ENTITY , ENTITY should be used with caution in ENTITY with other ENTITY and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t centrally acting drugs, ENTITY \t alcohol, ENTITY \n",
      "Sentences: \n",
      "\tGiven the primary CNS effects of paliperidone , INVEGA should be used with caution in combination with other centrally acting drugs and alcohol . \n",
      "\t Given the ENTITY ENTITY ENTITY of ENTITY , ENTITY should be used with caution in ENTITY with other ENTITY and ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t metronidazole, ENTITY \t coumarin, ENTITY \n",
      "Sentences: \n",
      "\tOral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin , resulting in a prolongation of prothrombin time . \n",
      "\t ENTITY has been reported to ENTITY the ENTITY of ENTITY and ENTITY , resulting in a ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t metronidazole, ENTITY \t warfarin, ENTITY \n",
      "Sentences: \n",
      "\tOral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin , resulting in a prolongation of prothrombin time . \n",
      "\t ENTITY has been reported to ENTITY the ENTITY of ENTITY and ENTITY , resulting in a ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t aspirin, ENTITY \t meloxicam, ENTITY \n",
      "Sentences: \n",
      "\tAspirin : Concomitant administration of aspirin ( 1000 mg TID ) to healthy volunteers tended to increase the AUC ( 10 % ) and Cmax ( 24 % ) of meloxicam . \n",
      "\t ENTITY : ENTITY ENTITY of ENTITY ( 1000 mg ENTITY ) to ENTITY tended to ENTITY the ENTITY ( 10 % ) and ENTITY ( 24 % ) of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t furosemide, ENTITY \t meloxicam, ENTITY \n",
      "Sentences: \n",
      "\tStudies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect . \n",
      "\t ENTITY with ENTITY and ENTITY have not demonstrated a ENTITY in ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t furosemide, ENTITY \t MOBIC, ENTITY \n",
      "Sentences: \n",
      "\tNevertheless , during concomitant therapy with furosemide and MOBIC , patients should be observed closely for signs of declining renal function , as well as to assure diuretic efficacy . \n",
      "\t Nevertheless , during ENTITY ENTITY with ENTITY and ENTITY , ENTITY should be observed closely for signs of ENTITY ENTITY , as well as to assure ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t NSAIDs, ENTITY \t lithium, ENTITY \n",
      "Sentences: \n",
      "\tLithium : In clinical trials , NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance . \n",
      "\t ENTITY : In ENTITY , ENTITY have produced an ENTITY of ENTITY ENTITY levels and a ENTITY in ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t warfarin, ENTITY \t warfarin, ENTITY \n",
      "Sentences: \n",
      "\tThe effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR ( International Normalized Ratio ) between 1.2 and 1.8 . \n",
      "\t The ENTITY of ENTITY on the ENTITY of ENTITY was studied in a ENTITY of ENTITY receiving ENTITY of ENTITY that produced an ENTITY ( ENTITY ) between 1.2 and 1.8 .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t NEXAVAR, ENTITY \t doxorubicin, ENTITY \n",
      "Sentences: \n",
      "\tConcomitant treatment with NEXAVAR resulted in a 21 % increase in the AUC of doxorubicin . \n",
      "\t ENTITY ENTITY with ENTITY resulted in a 21 % ENTITY in the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t doxorubicin, ENTITY \t NEXAVAR, ENTITY \n",
      "Sentences: \n",
      "\tCaution is recommended when administering doxorubicin with NEXAVAR . \n",
      "\t ENTITY is ENTITY when ENTITY ENTITY with ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ketoconazole, ENTITY \t azole antifungals, ENTITY \n",
      "Sentences: \n",
      "\tFor patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . \n",
      "\t For ENTITY receiving ENTITY or other potent ENTITY ENTITY such as other ENTITY ( eg , ENTITY , ENTITY ) or ENTITY ( eg , ENTITY , ENTITY ) or ENTITY or ENTITY , the ENTITY of ENTITY ENTITY is 2 mg ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ketoconazole, ENTITY \t itraconazole, ENTITY \n",
      "Sentences: \n",
      "\tFor patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . \n",
      "\t For ENTITY receiving ENTITY or other potent ENTITY ENTITY such as other ENTITY ( eg , ENTITY , ENTITY ) or ENTITY ( eg , ENTITY , ENTITY ) or ENTITY or ENTITY , the ENTITY of ENTITY ENTITY is 2 mg ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ketoconazole, ENTITY \t miconazole, ENTITY \n",
      "Sentences: \n",
      "\tFor patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . \n",
      "\t For ENTITY receiving ENTITY or other potent ENTITY ENTITY such as other ENTITY ( eg , ENTITY , ENTITY ) or ENTITY ( eg , ENTITY , ENTITY ) or ENTITY or ENTITY , the ENTITY of ENTITY ENTITY is 2 mg ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ketoconazole, ENTITY \t macrolide antibiotics, ENTITY \n",
      "Sentences: \n",
      "\tFor patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of DETROL LA is 2 mg daily . \n",
      "\t For ENTITY receiving ENTITY or other potent ENTITY ENTITY such as other ENTITY ( eg , ENTITY , ENTITY ) or ENTITY ( eg , ENTITY , ENTITY ) or ENTITY or ENTITY , the ENTITY of ENTITY ENTITY is 2 mg ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t digoxin, ENTITY \t metoclopramide, ENTITY \n",
      "Sentences: \n",
      "\tAbsorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) . \n",
      "\t ENTITY of ENTITY from the ENTITY may be ENTITY ( e.g. , ENTITY ) by ENTITY , whereas the ENTITY and/or extent of ENTITY of ENTITY from the ENTITY may be ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t paricalcitol, ENTITY \t ketoconazole, ENTITY \n",
      "Sentences: \n",
      "\tA multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . \n",
      "\t A ENTITY - ENTITY demonstrated that ENTITY ENTITY doubled ENTITY ENTITY . Since ENTITY is partially ENTITY by ENTITY and ENTITY le is known to be a strong ENTITY of ENTITY , ENTITY should be taken while ENTITY ENTITY with ENTITY and other strong ENTITY ENTITY including ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t paricalcitol, ENTITY \t ketoconazole, ENTITY \n",
      "Sentences: \n",
      "\tA multiple dose drug - drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole . \n",
      "\t A ENTITY - ENTITY demonstrated that ENTITY ENTITY doubled ENTITY ENTITY . Since ENTITY is partially ENTITY by ENTITY and ENTITY le is known to be a strong ENTITY of ENTITY , ENTITY should be taken while ENTITY ENTITY with ENTITY and other strong ENTITY ENTITY including ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t rimantadine HCl, ENTITY \t Cimetidine, ENTITY \n",
      "Sentences: \n",
      "\tWhen a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) . \n",
      "\t When a single 100 mg ENTITY of ENTITY was ENTITY one hour after the ENTITY of ENTITY ( 300 mg four times a ENTITY ) , the ENTITY total ENTITY ENTITY of this ENTITY in normal ENTITY was ENTITY by 18 % ( ENTITY to the ENTITY total ENTITY ENTITY in the same ENTITY in the ENTITY of ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t acetaminophen, ENTITY \t rimantadine, ENTITY \n",
      "Sentences: \n",
      "\tCoadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11 % . \n",
      "\t ENTITY with ENTITY ENTITY the ENTITY and ENTITY ENTITY for ENTITY by approximately 11 % .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t rimantadine, ENTITY \t aspirin, ENTITY \n",
      "Sentences: \n",
      "\tPeak plasma concentrations and AUC of rimantadine were reduced approximately 10 % in the presence of aspirin . \n",
      "\t ENTITY ENTITY and ENTITY of ENTITY were ENTITY approximately 10 % in the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Probenecid, ENTITY \t riboflavin, ENTITY \n",
      "Sentences: \n",
      "\tProbenecid - concurrent use decreases gastrointestinal absorption of riboflavin ; \n",
      "\t ENTITY - ENTITY use ENTITY ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Lithium, ENTITY \t lithium, ENTITY \n",
      "Sentences: \n",
      "\tLithium renal clearance is reduced by thiazides , increasing the risk of lithium toxicity . \n",
      "\t ENTITY ENTITY is ENTITY by ENTITY , ENTITY the ENTITY of ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t cimetidine, ENTITY \t FLOMAX, ENTITY \n",
      "Sentences: \n",
      "\tThe pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated . \n",
      "\t The ENTITY ENTITY between ENTITY and ENTITY was ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Vindesine, ENTITY \t vaccine, ENTITY \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t ENTITY can ENTITY with the ENTITY of the following ENTITY : - ENTITY : can cause ENTITY ENTITY - ENTITY depressants : can cause a predictable ENTITY - ENTITY ENTITY - ENTITY : may cause ENTITY - ENTITY : can cause ENTITY ENTITY - ENTITY : can ENTITY ENTITY ENTITY - ENTITY : may ENTITY the ENTITY of the ENTITY , may ENTITY the ENTITY of the ENTITY , and ENTITY ENTITY response to the ENTITY - ENTITY - ENTITY : may cause ENTITY and ENTITY - ENTITY : may ENTITY ENTITY response to the ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t vaccine, ENTITY \t Mitomycin - C, ENTITY - ENTITY \n",
      "Sentences: \n",
      "\tVindesine can interact with the drugs of the following categories : - Blood dyscrasia : can cause unpredictable myelotoxicity - Bone marrow depressants : can cause a predictable dose - related myelotoxicity - Radiation therapy : may cause marrow depression - Neurotoxic medications : can cause neurologic toxicity - Phenytoin : can increase seizure activity - Live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - Mitomycin - C : may cause shortness of breath and bronchospasm - Killed virus vaccines : may decrease patient 's response to the vaccine \n",
      "\t ENTITY can ENTITY with the ENTITY of the following ENTITY : - ENTITY : can cause ENTITY ENTITY - ENTITY depressants : can cause a predictable ENTITY - ENTITY ENTITY - ENTITY : may cause ENTITY - ENTITY : can cause ENTITY ENTITY - ENTITY : can ENTITY ENTITY ENTITY - ENTITY : may ENTITY the ENTITY of the ENTITY , may ENTITY the ENTITY of the ENTITY , and ENTITY ENTITY response to the ENTITY - ENTITY - ENTITY : may cause ENTITY and ENTITY - ENTITY : may ENTITY ENTITY response to the ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t anticonvulsants, ENTITY \t mifepristone, ENTITY \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort , and certain ENTITY ( ENTITY , ENTITY , ENTITY ) may ENTITY ENTITY ( ENTITY levels of ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t phenobarbital, ENTITY \t mifepristone, ENTITY \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort , and certain ENTITY ( ENTITY , ENTITY , ENTITY ) may ENTITY ENTITY ( ENTITY levels of ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t carbamazepine, ENTITY \t mifepristone, ENTITY \n",
      "Sentences: \n",
      "\tJohn s Wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) . \n",
      "\t John s Wort , and certain ENTITY ( ENTITY , ENTITY , ENTITY ) may ENTITY ENTITY ( ENTITY levels of ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t methylergonovine maleate, ENTITY \t ergot alkaloids, ENTITY \n",
      "Sentences: \n",
      "\tCaution should be exercised when Methergine ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or ergot alkaloids . \n",
      "\t ENTITY should be ENTITY when ENTITY ( ENTITY ) is used concurrently with other ENTITY or ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t diphosphonate, ENTITY \t Calcitonin ( salmon ), ENTITY ( salmon ) \n",
      "Sentences: \n",
      "\thowever , in patients with Paget 's Disease prior diphosphonate use appears to reduce the anti - resorptive response to Calcitonin ( salmon ) nasal spray . \n",
      "\t however , in ENTITY with ENTITY prior ENTITY use appears to ENTITY the ENTITY - ENTITY response to ENTITY ( salmon ) ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t SPIRIVA, ENTITY \t anticholinergic, ENTITY \n",
      "Sentences: \n",
      "\tHowever , the co administration of SPIRIVA with other anticholinergic containing drugs ( e.g. , ipratropium ) has not been studied and is therefore not recommended . \n",
      "\t However , the co ENTITY of ENTITY with other ENTITY containing ENTITY ( e.g. , ENTITY ) has not been studied and is therefore not recommended .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t SPIRIVA, ENTITY \t ipratropium, ENTITY \n",
      "Sentences: \n",
      "\tHowever , the co administration of SPIRIVA with other anticholinergic containing drugs ( e.g. , ipratropium ) has not been studied and is therefore not recommended . \n",
      "\t However , the co ENTITY of ENTITY with other ENTITY containing ENTITY ( e.g. , ENTITY ) has not been studied and is therefore not recommended .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t alcohol, ENTITY \t Diazepam, ENTITY \n",
      "Sentences: \n",
      "\tAccordingly , patients should be advised to avoid alcohol while taking REMERON SolTab . Diazepam : Concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects . \n",
      "\t Accordingly , ENTITY should be advised to avoid ENTITY while taking ENTITY ENTITY . ENTITY : ENTITY ENTITY of ENTITY ( 15 mg ) had a minimal ENTITY on ENTITY levels of ENTITY ( 15 mg ) in 12 ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t corticosteroids, ENTITY \t corticosteroid, ENTITY \n",
      "Sentences: \n",
      "\tDrugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response . \n",
      "\t ENTITY that ENTITY ENTITY such as ENTITY , ENTITY and ENTITY may ENTITY the ENTITY of ENTITY and may require ENTITY in ENTITY to achieve the desired ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t salicylate, ENTITY \t corticosteroid, ENTITY \n",
      "Sentences: \n",
      "\tThis could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn . \n",
      "\t This could lead to ENTITY ENTITY ENTITY or ENTITY the ENTITY of ENTITY ENTITY when ENTITY is withdrawn .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t corticosteroids, ENTITY \t anticoagulants, ENTITY \n",
      "Sentences: \n",
      "\tThe effect of corticosteroids on oral anticoagulants is variable . \n",
      "\t The ENTITY of ENTITY on ENTITY is ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, advise \n",
      "Entities: \t aspirin, ENTITY \t carbonic anhydrase inhibitors, ENTITY \n",
      "Sentences: \n",
      "\tCaution is advised for patients receiving high - dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high - dose aspirin and carbonic anhydrase inhibitors . \n",
      "\t ENTITY is advised for ENTITY receiving ENTITY - ENTITY ENTITY and ENTITY concomitantly , as ENTITY , ENTITY , ENTITY , ENTITY and ENTITY have been reported with ENTITY use of ENTITY - ENTITY ENTITY and ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t sympathomimetic pressor amines, ENTITY ENTITY \t monoamine oxidase inhibitors, ENTITY \n",
      "Sentences: \n",
      "\tMAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( MAOI ) . \n",
      "\t ENTITY - The ENTITY ENTITY of ENTITY ENTITY is markedly ENTITY in ENTITY receiving ENTITY ( ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t sympathomimetic pressor amines, ENTITY ENTITY \t MAOI, ENTITY \n",
      "Sentences: \n",
      "\tMAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( MAOI ) . \n",
      "\t ENTITY - The ENTITY ENTITY of ENTITY ENTITY is markedly ENTITY in ENTITY receiving ENTITY ( ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, advise \n",
      "Entities: \t diuretic, ENTITY \t perindopril, ENTITY \n",
      "Sentences: \n",
      "\tThe possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril . \n",
      "\t The possibility of ENTITY effects can be minimized by either ENTITY the ENTITY or ENTITY the ENTITY prior to ENTITY of ENTITY with ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t potassium - sparing diuretics, ENTITY - ENTITY ENTITY \t potassium, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t potassium - sparing diuretics, ENTITY - ENTITY ENTITY \t indomethacin, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t potassium - sparing diuretics, ENTITY - ENTITY ENTITY \t heparin, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t spironolactone, ENTITY \t indomethacin, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t spironolactone, ENTITY \t heparin, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t amiloride, ENTITY \t cyclosporine, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t triamterene, ENTITY \t cyclosporine, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t potassium, ENTITY \t indomethacin, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t potassium, ENTITY \t heparin, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t potassium, ENTITY \t cyclosporine, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) , ENTITY or other ENTITY capable of ENTITY ENTITY ( ENTITY , ENTITY , ENTITY and others ) can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t digoxin, ENTITY \t ACEON, ENTITY \n",
      "Sentences: \n",
      "\tDigoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . \n",
      "\t ENTITY : A ENTITY ENTITY has shown no effect on ENTITY ENTITY ENTITY when ENTITY with ENTITY ENTITY , but an ENTITY of ENTITY on the ENTITY ENTITY of ENTITY / ENTITY has not been excluded .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t digoxin, ENTITY \t digoxin, ENTITY \n",
      "Sentences: \n",
      "\tDigoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . \n",
      "\t ENTITY : A ENTITY ENTITY has shown no effect on ENTITY ENTITY ENTITY when ENTITY with ENTITY ENTITY , but an ENTITY of ENTITY on the ENTITY ENTITY of ENTITY / ENTITY has not been excluded .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t digoxin, ENTITY \t perindopril, ENTITY \n",
      "Sentences: \n",
      "\tDigoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . \n",
      "\t ENTITY : A ENTITY ENTITY has shown no effect on ENTITY ENTITY ENTITY when ENTITY with ENTITY ENTITY , but an ENTITY of ENTITY on the ENTITY ENTITY of ENTITY / ENTITY has not been excluded .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t digoxin, ENTITY \t perindoprilat, ENTITY \n",
      "Sentences: \n",
      "\tDigoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . \n",
      "\t ENTITY : A ENTITY ENTITY has shown no effect on ENTITY ENTITY ENTITY when ENTITY with ENTITY ENTITY , but an ENTITY of ENTITY on the ENTITY ENTITY of ENTITY / ENTITY has not been excluded .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ACEON, ENTITY \t digoxin, ENTITY \n",
      "Sentences: \n",
      "\tDigoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . \n",
      "\t ENTITY : A ENTITY ENTITY has shown no effect on ENTITY ENTITY ENTITY when ENTITY with ENTITY ENTITY , but an ENTITY of ENTITY on the ENTITY ENTITY of ENTITY / ENTITY has not been excluded .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ACEON, ENTITY \t perindopril, ENTITY \n",
      "Sentences: \n",
      "\tDigoxin : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets , but an effect of digoxin on the plasma concentration of perindopril / perindoprilat has not been excluded . \n",
      "\t ENTITY : A ENTITY ENTITY has shown no effect on ENTITY ENTITY ENTITY when ENTITY with ENTITY ENTITY , but an ENTITY of ENTITY on the ENTITY ENTITY of ENTITY / ENTITY has not been excluded .\n",
      "\n",
      "\n",
      "Predicted Relation: \t int, effect \n",
      "Entities: \t perindopril, ENTITY \t gentamicin, ENTITY \n",
      "Sentences: \n",
      "\tGentamicin : Animal data have suggested the possibility of interaction between perindopril and gentamicin . \n",
      "\t ENTITY : ENTITY ENTITY have suggested the possibility of ENTITY between ENTITY and ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t pentazocine, ENTITY \t opioid agonist analgesic, ENTITY agonist ENTITY \n",
      "Sentences: \n",
      "\tInteraction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . \n",
      "\t ENTITY with ENTITY / ENTITY ENTITY : ENTITY / ENTITY ENTITY ( i.e. , ENTITY , ENTITY , ENTITY , or ENTITY ) should NOT be ENTITY to ENTITY who have received or are receiving a ENTITY of ENTITY with a proof ENTITY agonist ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t nalbuphine, ENTITY \t opioid agonist analgesic, ENTITY agonist ENTITY \n",
      "Sentences: \n",
      "\tInteraction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . \n",
      "\t ENTITY with ENTITY / ENTITY ENTITY : ENTITY / ENTITY ENTITY ( i.e. , ENTITY , ENTITY , ENTITY , or ENTITY ) should NOT be ENTITY to ENTITY who have received or are receiving a ENTITY of ENTITY with a proof ENTITY agonist ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t butorphanol, ENTITY \t opioid agonist analgesic, ENTITY agonist ENTITY \n",
      "Sentences: \n",
      "\tInteraction with Mixed Agonist / Antagonist Opioid Analgesics : Agonist / antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic . \n",
      "\t ENTITY with ENTITY / ENTITY ENTITY : ENTITY / ENTITY ENTITY ( i.e. , ENTITY , ENTITY , ENTITY , or ENTITY ) should NOT be ENTITY to ENTITY who have received or are receiving a ENTITY of ENTITY with a proof ENTITY agonist ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t Dopamine antagonists, ENTITY \t Permax, ENTITY \n",
      "Sentences: \n",
      "\tDopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; \n",
      "\t ENTITY , such as the ENTITY ( ENTITY , ENTITY , ENTITY ) or ENTITY , ordinarily should not be ENTITY concurrently with ENTITY ( a ENTITY ENTITY ) ;\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t neuroleptics, ENTITY \t Permax, ENTITY \n",
      "Sentences: \n",
      "\tDopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; \n",
      "\t ENTITY , such as the ENTITY ( ENTITY , ENTITY , ENTITY ) or ENTITY , ordinarily should not be ENTITY concurrently with ENTITY ( a ENTITY ENTITY ) ;\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t metoclopramide, ENTITY \t dopamine agonist, ENTITY ENTITY \n",
      "Sentences: \n",
      "\tDopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with Permax ( a dopamine agonist ) ; \n",
      "\t ENTITY , such as the ENTITY ( ENTITY , ENTITY , ENTITY ) or ENTITY , ordinarily should not be ENTITY concurrently with ENTITY ( a ENTITY ENTITY ) ;\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Aminoglutethimide, ENTITY \t MPA, ENTITY \n",
      "Sentences: \n",
      "\tAminoglutethimide administered concomitantly with depo - subQ provera 104 may significantly decrease the serum concentrations of MPA . \n",
      "\t ENTITY ENTITY ENTITY with ENTITY - ENTITY ENTITY 104 may significantly ENTITY the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t depo - subQ provera 104, ENTITY - ENTITY ENTITY 104 \t MPA, ENTITY \n",
      "Sentences: \n",
      "\tAminoglutethimide administered concomitantly with depo - subQ provera 104 may significantly decrease the serum concentrations of MPA . \n",
      "\t ENTITY ENTITY ENTITY with ENTITY - ENTITY ENTITY 104 may significantly ENTITY the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t MYCAMINE, ENTITY \t mycophenolate mofetil, ENTITY \n",
      "Sentences: \n",
      "\tA total of 11 clinical drug - drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin . \n",
      "\t A total of 11 ENTITY - ENTITY were conducted in ENTITY to ENTITY the ENTITY for ENTITY between ENTITY and ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t MAO inhibitors, ENTITY \t pseudoephedrine, ENTITY \n",
      "Sentences: \n",
      "\tMAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine . \n",
      "\t ENTITY and ENTITY ENTITY the ENTITY ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t beta adrenergic blockers, ENTITY \t pseudoephedrine, ENTITY \n",
      "Sentences: \n",
      "\tMAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine . \n",
      "\t ENTITY and ENTITY ENTITY the ENTITY ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t TOBI, ENTITY \t dornase alfa, ENTITY \n",
      "Sentences: \n",
      "\tIn clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta)-agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . \n",
      "\t In ENTITY of ENTITY , ENTITY taking ENTITY concomitantly with ENTITY ( ENTITY , ENTITY ) , ( ENTITY , ENTITY , other ENTITY - ENTITY ENTITY , or ENTITY demonstrated adverse experience ENTITY similar to the ENTITY as a whole .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t TOBI, ENTITY \t aminoglycosides, ENTITY \n",
      "Sentences: \n",
      "\tIn clinical studies of TOBI , patients taking TOBI concomitantly with dornase alfa ( PULMOZYME , Genentech ) , ( beta)-agonists , inhaled corticosteroids , other anti - pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole . \n",
      "\t In ENTITY of ENTITY , ENTITY taking ENTITY concomitantly with ENTITY ( ENTITY , ENTITY ) , ( ENTITY , ENTITY , other ENTITY - ENTITY ENTITY , or ENTITY demonstrated adverse experience ENTITY similar to the ENTITY as a whole .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t diuretics, ENTITY \t aminoglycoside, ENTITY \n",
      "Sentences: \n",
      "\tSome diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue . \n",
      "\t Some ENTITY can ENTITY ENTITY ENTITY by ENTITY ENTITY ENTITY in ENTITY and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t Mitotane, ENTITY \t coumarin - type anticoagulants, ENTITY - ENTITY \n",
      "Sentences: \n",
      "\tTherefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin - type anticoagulants . \n",
      "\t Therefore , ENTITY should closely monitor ENTITY for a ENTITY in ENTITY ENTITY when ENTITY ENTITY to ENTITY on ENTITY - ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t fluconazole, ENTITY \t midazolam, ENTITY \n",
      "Sentences: \n",
      "\tDrugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . \n",
      "\t ENTITY such as ENTITY , ENTITY , ENTITY , ENTITY , ENTITY and ENTITY were shown to significantly ENTITY the ENTITY and ENTITY of ENTITY ENTITY ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t itraconazole, ENTITY \t midazolam, ENTITY \n",
      "Sentences: \n",
      "\tDrugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam . \n",
      "\t ENTITY such as ENTITY , ENTITY , ENTITY , ENTITY , ENTITY and ENTITY were shown to significantly ENTITY the ENTITY and ENTITY of ENTITY ENTITY ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ritonavir, ENTITY \t nelfinavir, ENTITY \n",
      "Sentences: \n",
      "\tAlthough not studied , the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam . \n",
      "\t Although not studied , the potent ENTITY inhibitors ENTITY and ENTITY may cause ENTITY and ENTITY ENTITY and ENTITY due to a ENTITY in ENTITY ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t phenytoin, ENTITY \t midazolam, ENTITY \n",
      "Sentences: \n",
      "\tInducers of CYP3A4 Isozymes : Cytochrome P450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies . \n",
      "\t ENTITY of ENTITY ENTITY : ENTITY , such as ENTITY , ENTITY , and ENTITY , ENTITY ENTITY and caused a markedly ENTITY ENTITY and ENTITY of ENTITY in ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t VERSED Syrup, ENTITY ENTITY \t narcotics, ENTITY \n",
      "Sentences: \n",
      "\tThe sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . \n",
      "\t The ENTITY of ENTITY ENTITY is accentuated by any concomitantly ENTITY ENTITY which ENTITY the ENTITY , particularly ENTITY ( eg , ENTITY , ENTITY and ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t VERSED Syrup, ENTITY ENTITY \t morphine, ENTITY \n",
      "Sentences: \n",
      "\tThe sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . \n",
      "\t The ENTITY of ENTITY ENTITY is accentuated by any concomitantly ENTITY ENTITY which ENTITY the ENTITY , particularly ENTITY ( eg , ENTITY , ENTITY and ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t VERSED Syrup, ENTITY ENTITY \t meperidine, ENTITY \n",
      "Sentences: \n",
      "\tThe sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . \n",
      "\t The ENTITY of ENTITY ENTITY is accentuated by any concomitantly ENTITY ENTITY which ENTITY the ENTITY , particularly ENTITY ( eg , ENTITY , ENTITY and ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t VERSED Syrup, ENTITY ENTITY \t fentanyl, ENTITY \n",
      "Sentences: \n",
      "\tThe sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . \n",
      "\t The ENTITY of ENTITY ENTITY is accentuated by any concomitantly ENTITY ENTITY which ENTITY the ENTITY , particularly ENTITY ( eg , ENTITY , ENTITY and ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t VERSED Syrup, ENTITY ENTITY \t droperidol, ENTITY \n",
      "Sentences: \n",
      "\tThe sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol . \n",
      "\t The ENTITY of ENTITY ENTITY is accentuated by any concomitantly ENTITY ENTITY which ENTITY the ENTITY , particularly ENTITY ( eg , ENTITY , ENTITY and ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY and ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t penicillin, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t thiopental, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t thyroxine, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t triiodothyronine, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t phenytoin, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t sulfinpyrazone, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t naproxen, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t warfarin, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t methotrexate, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Salicylate, ENTITY \t corticosteroids, ENTITY \n",
      "Sentences: \n",
      "\tSalicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids . \n",
      "\t ENTITY competes with a number of ENTITY for ENTITY , notably ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and possibly ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t hypoglycemic agents, ENTITY \t hypoglycemic agents, ENTITY \n",
      "Sentences: \n",
      "\tOral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents . \n",
      "\t ENTITY ENTITY ENTITY may ENTITY the ENTITY of ENTITY ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, effect \n",
      "Entities: \t Oxandrolone, ENTITY \t hypoglycemic agents, ENTITY \n",
      "Sentences: \n",
      "\tOral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents . \n",
      "\t ENTITY ENTITY ENTITY may ENTITY the ENTITY of ENTITY ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t tolbutamide, ENTITY \t sodium salicylate, ENTITY \n",
      "Sentences: \n",
      "\tIn a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein - bound teniposide in fresh human serum to a small but significant extent . \n",
      "\t In a ENTITY in which 34 different ENTITY were ENTITY , ENTITY ENTITY ENTITY of ENTITY , ENTITY and ENTITY displaced ENTITY - ENTITY ENTITY in ENTITY ENTITY ENTITY to a small but significant extent .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t methotrexate, ENTITY \t teniposide, ENTITY \n",
      "Sentences: \n",
      "\tAn increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide . \n",
      "\t An ENTITY in ENTITY ENTITY of ENTITY was observed ENTITY in the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t cholinesterase inhibitors, ENTITY \t succinylcholine, ENTITY \n",
      "Sentences: \n",
      "\tUse with Cholinomimetics and Other Cholinesterase Inhibitors : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol . \n",
      "\t Use with ENTITY and Other ENTITY : A ENTITY may be expected when ENTITY are given concurrently with ENTITY , similar ENTITY blocking agents or ENTITY such as ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t TRENTAL, ENTITY \t anticoagulants, ENTITY \n",
      "Sentences: \n",
      "\tAlthough a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors . \n",
      "\t Although a causal ENTITY has not been established , there have been ENTITY of ENTITY and/or ENTITY ENTITY in ENTITY ENTITY ENTITY with and without ENTITY or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t TRENTAL, ENTITY \t platelet aggregation inhibitors, ENTITY \n",
      "Sentences: \n",
      "\tAlthough a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors . \n",
      "\t Although a causal ENTITY has not been established , there have been ENTITY of ENTITY and/or ENTITY ENTITY in ENTITY ENTITY ENTITY with and without ENTITY or ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t TRENTAL, ENTITY \t theophylline, ENTITY \n",
      "Sentences: \n",
      "\tConcomitant administration of TRENTAL and theophylline -containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals . \n",
      "\t ENTITY ENTITY of ENTITY and ENTITY -containing ENTITY leads to ENTITY ENTITY ENTITY and ENTITY ENTITY in some ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t methyldopa, ENTITY \t ferrous sulfate, ENTITY \n",
      "Sentences: \n",
      "\tSeveral studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate . \n",
      "\t Several ENTITY demonstrate a ENTITY in the ENTITY of ENTITY when it is ENTITY with ENTITY or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t methyldopa, ENTITY \t ferrous gluconate, ENTITY \n",
      "Sentences: \n",
      "\tSeveral studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate . \n",
      "\t Several ENTITY demonstrate a ENTITY in the ENTITY of ENTITY when it is ENTITY with ENTITY or ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t azathioprine, ENTITY \t azathioprine, ENTITY \n",
      "Sentences: \n",
      "\tAzathioprine / Mycophenolate Mofetil : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil . \n",
      "\t ENTITY / ENTITY ENTITY : Given that ENTITY and ENTITY ENTITY ENTITY , it is recommended that ENTITY not be ENTITY ENTITY with ENTITY or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t MPA, ENTITY \t mycophenolate mofetil, ENTITY \n",
      "Sentences: \n",
      "\tCholestyramine and Drugs that Bind Bile Acids : These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil . \n",
      "\t ENTITY and ENTITY that ENTITY : These ENTITY interrupt ENTITY ENTITY and ENTITY ENTITY ENTITY when ENTITY with ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t Myfortic, ENTITY \t cholestyramine, ENTITY \n",
      "Sentences: \n",
      "\tTherefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . \n",
      "\t Therefore , do not administer ENTITY with ENTITY or other ENTITY that may ENTITY ENTITY ENTITY or ENTITY that may ENTITY ENTITY , for example ENTITY ENTITY or ENTITY , because of the potential to ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Myfortic, ENTITY \t Myfortic, ENTITY \n",
      "Sentences: \n",
      "\tTherefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . \n",
      "\t Therefore , do not administer ENTITY with ENTITY or other ENTITY that may ENTITY ENTITY ENTITY or ENTITY that may ENTITY ENTITY , for example ENTITY ENTITY or ENTITY , because of the potential to ENTITY the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t activated charcoal, ENTITY \t Myfortic, ENTITY \n",
      "Sentences: \n",
      "\tTherefore , do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of Myfortic . \n",
      "\t Therefore , do not administer ENTITY with ENTITY or other ENTITY that may ENTITY ENTITY ENTITY or ENTITY that may ENTITY ENTITY , for example ENTITY ENTITY or ENTITY , because of the potential to ENTITY the ENTITY of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t Myfortic, ENTITY \t contraceptives, ENTITY \n",
      "Sentences: \n",
      "\tOral Contraceptives : Given the different metabolism of Myfortic and oral contraceptives , no drug interaction between these two classes of drug is expected . \n",
      "\t ENTITY : Given the different ENTITY of ENTITY and ENTITY , ENTITY between these two classes of ENTITY is expected .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, effect \n",
      "Entities: \t contraceptives, ENTITY \t Myfortic, ENTITY \n",
      "Sentences: \n",
      "\tTherefore , it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered . \n",
      "\t Therefore , it is ENTITY that ENTITY are ENTITY ENTITY with ENTITY with ENTITY and additional ENTITY methods be considered .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t Live Vaccines, ENTITY \t Myfortic, ENTITY \n",
      "Sentences: \n",
      "\tLive Vaccines : During treatment with Myfortic , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective . \n",
      "\t ENTITY : During ENTITY with ENTITY , the use of ENTITY ENTITY ENTITY should be avoided and ENTITY should be advised that ENTITY may be less ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t megestrol acetate, ENTITY \t indinavir, ENTITY \n",
      "Sentences: \n",
      "\tA pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters ( ~36 % for Cmax and ~28 % for AUC ) of indinavir . \n",
      "\t A ENTITY demonstrated that ENTITY of ENTITY and ENTITY ENTITY in a significant ENTITY in the ENTITY ENTITY ( ~36 % for ENTITY and ~28 % for ENTITY ) of ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t methsuximide, ENTITY \t phenytoin, ENTITY \n",
      "Sentences: \n",
      "\tSince Celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) . \n",
      "\t Since ENTITY ( ENTITY ) may ENTITY with concurrently ENTITY ENTITY , ENTITY level ENTITY of these ENTITY may be necessary ( eg ENTITY may ENTITY the ENTITY ENTITY of ENTITY and ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t methsuximide, ENTITY \t phenobarbital, ENTITY \n",
      "Sentences: \n",
      "\tSince Celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) . \n",
      "\t Since ENTITY ( ENTITY ) may ENTITY with concurrently ENTITY ENTITY , ENTITY level ENTITY of these ENTITY may be necessary ( eg ENTITY may ENTITY the ENTITY ENTITY of ENTITY and ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t vancomycin, ENTITY \t anesthetic agents, ENTITY \n",
      "Sentences: \n",
      "\tConcomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine - like flushing and anaphylactoid reactions . \n",
      "\t ENTITY ENTITY of ENTITY and ENTITY has been ENTITY ENTITY and ENTITY - like ENTITY and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t Melatonin, ENTITY \t melatonin, ENTITY \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t ENTITY may ENTITY with the following ENTITY : ENTITY and other ENTITY ( may lower ENTITY ENTITY ) , ENTITY ( ENTITY of ENTITY is ENTITY with ENTITY ) , ENTITY ( may ENTITY ENTITY ENTITY ) , ENTITY ( ENTITY of ENTITY when ENTITY ) , ENTITY ( ENTITY of ENTITY with ENTITY can ENTITY ENTITY in ENTITY ) , ENTITY and other ENTITY ( may result in ENTITY ENTITY and an ENTITY ENTITY of ENTITY ) , and ENTITY ( ENTITY of ENTITY and ENTITY may ENTITY the ENTITY of the ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t melatonin, ENTITY \t progestin, ENTITY \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t ENTITY may ENTITY with the following ENTITY : ENTITY and other ENTITY ( may lower ENTITY ENTITY ) , ENTITY ( ENTITY of ENTITY is ENTITY with ENTITY ) , ENTITY ( may ENTITY ENTITY ENTITY ) , ENTITY ( ENTITY of ENTITY when ENTITY ) , ENTITY ( ENTITY of ENTITY with ENTITY can ENTITY ENTITY in ENTITY ) , ENTITY and other ENTITY ( may result in ENTITY ENTITY and an ENTITY ENTITY of ENTITY ) , and ENTITY ( ENTITY of ENTITY and ENTITY may ENTITY the ENTITY of the ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t melatonin, ENTITY \t corticosteroids, ENTITY \n",
      "Sentences: \n",
      "\tMelatonin may interact with the following drugs : aspirin and other NSAIDs ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) . \n",
      "\t ENTITY may ENTITY with the following ENTITY : ENTITY and other ENTITY ( may lower ENTITY ENTITY ) , ENTITY ( ENTITY of ENTITY is ENTITY with ENTITY ) , ENTITY ( may ENTITY ENTITY ENTITY ) , ENTITY ( ENTITY of ENTITY when ENTITY ) , ENTITY ( ENTITY of ENTITY with ENTITY can ENTITY ENTITY in ENTITY ) , ENTITY and other ENTITY ( may result in ENTITY ENTITY and an ENTITY ENTITY of ENTITY ) , and ENTITY ( ENTITY of ENTITY and ENTITY may ENTITY the ENTITY of the ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t sympathomimetic pressor amines, ENTITY ENTITY \t monoamine oxidase inhibitors, ENTITY \n",
      "Sentences: \n",
      "\tMAO Inhibitors : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( MAOI ) . \n",
      "\t ENTITY : The ENTITY ENTITY of ENTITY ENTITY is markedly ENTITY in ENTITY receiving ENTITY ( ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t sympathomimetic pressor amines, ENTITY ENTITY \t MAOI, ENTITY \n",
      "Sentences: \n",
      "\tMAO Inhibitors : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( MAOI ) . \n",
      "\t ENTITY : The ENTITY ENTITY of ENTITY ENTITY is markedly ENTITY in ENTITY receiving ENTITY ( ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Phenobarbital, ENTITY \t montelukast, ENTITY \n",
      "Sentences: \n",
      "\tPhenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . \n",
      "\t ENTITY , which induces ENTITY , ENTITY the ENTITY of ENTITY approximately 40 % following a single 10-mg ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Phenobarbital, ENTITY \t montelukast, ENTITY \n",
      "Sentences: \n",
      "\tPhenobarbital , which induces hepatic metabolism , decreased the AUC of montelukast approximately 40 % following a single 10-mg dose of montelukast . \n",
      "\t ENTITY , which induces ENTITY , ENTITY the ENTITY of ENTITY approximately 40 % following a single 10-mg ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t pseudoephedrine, ENTITY \t ProAmatine, ENTITY \n",
      "Sentences: \n",
      "\tThe use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . \n",
      "\t The ENTITY ENTITY that ENTITY ENTITY - ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY or ENTITY ) may ENTITY or ENTITY the ENTITY ENTITY of ENTITY . Therefore , caution should be used when ENTITY is ENTITY concomitantly with ENTITY that cause ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t ephedrine, ENTITY \t ProAmatine, ENTITY \n",
      "Sentences: \n",
      "\tThe use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . \n",
      "\t The ENTITY ENTITY that ENTITY ENTITY - ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY or ENTITY ) may ENTITY or ENTITY the ENTITY ENTITY of ENTITY . Therefore , caution should be used when ENTITY is ENTITY concomitantly with ENTITY that cause ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t phenylpropanolamine, ENTITY \t ProAmatine, ENTITY \n",
      "Sentences: \n",
      "\tThe use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . \n",
      "\t The ENTITY ENTITY that ENTITY ENTITY - ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY or ENTITY ) may ENTITY or ENTITY the ENTITY ENTITY of ENTITY . Therefore , caution should be used when ENTITY is ENTITY concomitantly with ENTITY that cause ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t dihydroergotamine, ENTITY \t ProAmatine, ENTITY \n",
      "Sentences: \n",
      "\tThe use of drugs that stimulate alpha - adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of ProAmatine . Therefore , caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction . \n",
      "\t The ENTITY ENTITY that ENTITY ENTITY - ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY or ENTITY ) may ENTITY or ENTITY the ENTITY ENTITY of ENTITY . Therefore , caution should be used when ENTITY is ENTITY concomitantly with ENTITY that cause ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t Thalidomide, ENTITY \t barbiturates, ENTITY \n",
      "Sentences: \n",
      "\tThalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine . \n",
      "\t ENTITY has been reported to ENTITY the ENTITY of ENTITY , ENTITY , ENTITY , and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t norethindrone, ENTITY \t ethinyl estradiol, ENTITY \n",
      "Sentences: \n",
      "\tOral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . \n",
      "\t ENTITY : In 10 ENTITY ENTITY , the ENTITY of ENTITY and ENTITY following ENTITY of a ENTITY containing 1.0 mg of ENTITY and 75 g of ENTITY ENTITY were studied .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t norethindrone, ENTITY \t norethindrone acetate, ENTITY \n",
      "Sentences: \n",
      "\tOral Contraceptives : In 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied . \n",
      "\t ENTITY : In 10 ENTITY ENTITY , the ENTITY of ENTITY and ENTITY following ENTITY of a ENTITY containing 1.0 mg of ENTITY and 75 g of ENTITY ENTITY were studied .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t salicylate, ENTITY \t methylprednisolone, ENTITY \n",
      "Sentences: \n",
      "\tThis could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn . \n",
      "\t This could lead to ENTITY ENTITY ENTITY or ENTITY the ENTITY of ENTITY ENTITY when ENTITY is withdrawn .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t DEMSER, ENTITY \t CNS depressants, ENTITY ENTITY \n",
      "Sentences: \n",
      "\tConcurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects . \n",
      "\t ENTITY use of ENTITY with ENTITY or other ENTITY ENTITY can ENTITY their ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t terfenadine, ENTITY \t terfenadine, ENTITY \n",
      "Sentences: \n",
      "\tItraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post - marketing sources . \n",
      "\t ENTITY : ENTITY and ENTITY ENTITY ENTITY ENTITY have been reported during ENTITY use of ENTITY and ENTITY in ENTITY of ENTITY and from ENTITY ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t terfenadine, ENTITY \t itraconazole, ENTITY \n",
      "Sentences: \n",
      "\tItraconazole : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post - marketing sources . \n",
      "\t ENTITY : ENTITY and ENTITY ENTITY ENTITY ENTITY have been reported during ENTITY use of ENTITY and ENTITY in ENTITY of ENTITY and from ENTITY ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t erythromycin, ENTITY \t clarithromycin, ENTITY \n",
      "Sentences: \n",
      "\tMacrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . \n",
      "\t ENTITY : ENTITY indicate that ENTITY and ENTITY can exert an ENTITY on ENTITY ENTITY by a ENTITY which may be similar to that of ENTITY , but to a lesser extent .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t clarithromycin, ENTITY \t ketoconazole, ENTITY \n",
      "Sentences: \n",
      "\tMacrolides : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent . \n",
      "\t ENTITY : ENTITY indicate that ENTITY and ENTITY can exert an ENTITY on ENTITY ENTITY by a ENTITY which may be similar to that of ENTITY , but to a lesser extent .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t terfenadine, ENTITY \t troleandomycin, ENTITY \n",
      "Sentences: \n",
      "\tConcomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : Pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended . \n",
      "\t ENTITY ENTITY of ENTITY with ENTITY , ENTITY , or ENTITY is contraindicated : Pending full ENTITY of ENTITY ENTITY , ENTITY ENTITY of ENTITY with other ENTITY , including ENTITY , is not recommended .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t spironolactone, ENTITY \t ACE inhibitors, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY ) or ENTITY concomitantly with ENTITY can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t triamterene, ENTITY \t ACE inhibitors, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY ) or ENTITY concomitantly with ENTITY can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t amiloride, ENTITY \t ACE inhibitors, ENTITY \n",
      "Sentences: \n",
      "\tUse of potassium - sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia . \n",
      "\t Use of ENTITY - ENTITY ENTITY ( ENTITY , ENTITY , ENTITY ) or ENTITY concomitantly with ENTITY can ENTITY the ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t oxybutynin chloride, ENTITY \t DITROPAN XL, ENTITY \n",
      "Sentences: \n",
      "\tMean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole , a potent CYP3A4 inhibitor . \n",
      "\t ENTITY ENTITY ENTITY ENTITY were approximately 2 fold higher when ENTITY was ENTITY with ENTITY , a potent ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t oxybutynin chloride, ENTITY \t ketoconazole, ENTITY \n",
      "Sentences: \n",
      "\tMean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole , a potent CYP3A4 inhibitor . \n",
      "\t ENTITY ENTITY ENTITY ENTITY were approximately 2 fold higher when ENTITY was ENTITY with ENTITY , a potent ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t antimycotic agents, ENTITY \t oxybutynin, ENTITY \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t Other ENTITY of the ENTITY enzyme system , such as ENTITY ( e.g. , ENTITY and ENTITY ) or ENTITY ( e.g. , ENTITY and ENTITY ) , may alter ENTITY mean ENTITY ( i.e. , ENTITY and ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t macrolide antibiotics, ENTITY \t oxybutynin, ENTITY \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t Other ENTITY of the ENTITY enzyme system , such as ENTITY ( e.g. , ENTITY and ENTITY ) or ENTITY ( e.g. , ENTITY and ENTITY ) , may alter ENTITY mean ENTITY ( i.e. , ENTITY and ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t erythromycin, ENTITY \t oxybutynin, ENTITY \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t Other ENTITY of the ENTITY enzyme system , such as ENTITY ( e.g. , ENTITY and ENTITY ) or ENTITY ( e.g. , ENTITY and ENTITY ) , may alter ENTITY mean ENTITY ( i.e. , ENTITY and ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t clarithromycin, ENTITY \t oxybutynin, ENTITY \n",
      "Sentences: \n",
      "\tOther inhibitors of the cytochrome P450 3A4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , Cmax and AUC ) . \n",
      "\t Other ENTITY of the ENTITY enzyme system , such as ENTITY ( e.g. , ENTITY and ENTITY ) or ENTITY ( e.g. , ENTITY and ENTITY ) , may alter ENTITY mean ENTITY ( i.e. , ENTITY and ENTITY ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t propoxyphene, ENTITY \t CNS depressants, ENTITY ENTITY \n",
      "Sentences: \n",
      "\tThe CNS - depressant effect of propoxyphene is additive with that of other CNS depressants , including alcohol . \n",
      "\t The ENTITY - ENTITY ENTITY of ENTITY is additive with that of other ENTITY ENTITY , including ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t propoxyphene, ENTITY \t alcohol, ENTITY \n",
      "Sentences: \n",
      "\tThe CNS - depressant effect of propoxyphene is additive with that of other CNS depressants , including alcohol . \n",
      "\t The ENTITY - ENTITY ENTITY of ENTITY is additive with that of other ENTITY ENTITY , including ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t atropine, ENTITY \t atropine, ENTITY \n",
      "Sentences: \n",
      "\tWhen atropine and pralidoxime are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when atropine is used alone . \n",
      "\t When ENTITY and ENTITY are used together , the signs of ENTITY ( ENTITY , ENTITY , ENTITY , ENTITY of the ENTITY and ENTITY ) may occur earlier than might be expected when ENTITY is used alone .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t pralidoxime, ENTITY \t atropine, ENTITY \n",
      "Sentences: \n",
      "\tWhen atropine and pralidoxime are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when atropine is used alone . \n",
      "\t When ENTITY and ENTITY are used together , the signs of ENTITY ( ENTITY , ENTITY , ENTITY , ENTITY of the ENTITY and ENTITY ) may occur earlier than might be expected when ENTITY is used alone .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t cimetidine, ENTITY \t pramipexole, ENTITY \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t Other ENTITY eliminated via ENTITY : ENTITY ENTITY suggests that ENTITY of ENTITY that are ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) ENTITY the ENTITY ENTITY of ENTITY by about 20 % , while those ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) are likely to have little ENTITY on the ENTITY ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t ranitidine, ENTITY \t pramipexole, ENTITY \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t Other ENTITY eliminated via ENTITY : ENTITY ENTITY suggests that ENTITY of ENTITY that are ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) ENTITY the ENTITY ENTITY of ENTITY by about 20 % , while those ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) are likely to have little ENTITY on the ENTITY ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t diltiazem, ENTITY \t pramipexole, ENTITY \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t Other ENTITY eliminated via ENTITY : ENTITY ENTITY suggests that ENTITY of ENTITY that are ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) ENTITY the ENTITY ENTITY of ENTITY by about 20 % , while those ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) are likely to have little ENTITY on the ENTITY ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t triamterene, ENTITY \t pramipexole, ENTITY \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t Other ENTITY eliminated via ENTITY : ENTITY ENTITY suggests that ENTITY of ENTITY that are ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) ENTITY the ENTITY ENTITY of ENTITY by about 20 % , while those ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) are likely to have little ENTITY on the ENTITY ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t quinidine, ENTITY \t pramipexole, ENTITY \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t Other ENTITY eliminated via ENTITY : ENTITY ENTITY suggests that ENTITY of ENTITY that are ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) ENTITY the ENTITY ENTITY of ENTITY by about 20 % , while those ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) are likely to have little ENTITY on the ENTITY ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t quinine, ENTITY \t pramipexole, ENTITY \n",
      "Sentences: \n",
      "\tOther drugs eliminated via renal secretion : Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole . \n",
      "\t Other ENTITY eliminated via ENTITY : ENTITY ENTITY suggests that ENTITY of ENTITY that are ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) ENTITY the ENTITY ENTITY of ENTITY by about 20 % , while those ENTITY by the ENTITY ( e.g. , ENTITY , ENTITY , ENTITY , ENTITY , and ENTITY ) are likely to have little ENTITY on the ENTITY ENTITY of ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t Anticoagulants, ENTITY \t acetylsalicylic acid, ENTITY \n",
      "Sentences: \n",
      "\tAnticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . \n",
      "\t ENTITY ( such as ENTITY and ENTITY ) and ENTITY that alter ENTITY ( such as ENTITY , ENTITY , and ENTITY / ENTITY ) may ENTITY the ENTITY of ENTITY if ENTITY prior to , during , or after ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t heparin, ENTITY \t acetylsalicylic acid, ENTITY \n",
      "Sentences: \n",
      "\tAnticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . \n",
      "\t ENTITY ( such as ENTITY and ENTITY ) and ENTITY that alter ENTITY ( such as ENTITY , ENTITY , and ENTITY / ENTITY ) may ENTITY the ENTITY of ENTITY if ENTITY prior to , during , or after ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t vitamin K antagonists, ENTITY \t TNKase, ENTITY \n",
      "Sentences: \n",
      "\tAnticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . \n",
      "\t ENTITY ( such as ENTITY and ENTITY ) and ENTITY that alter ENTITY ( such as ENTITY , ENTITY , and ENTITY / ENTITY ) may ENTITY the ENTITY of ENTITY if ENTITY prior to , during , or after ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t dipyridamole, ENTITY \t TNKase, ENTITY \n",
      "Sentences: \n",
      "\tAnticoagulants ( such as heparin and vitamin K antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and GP IIb / IIIa inhibitors ) may increase the risk of bleeding if administered prior to , during , or after TNKase therapy . \n",
      "\t ENTITY ( such as ENTITY and ENTITY ) and ENTITY that alter ENTITY ( such as ENTITY , ENTITY , and ENTITY / ENTITY ) may ENTITY the ENTITY of ENTITY if ENTITY prior to , during , or after ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t theophylline, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t cisapride, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t antipyrine, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t caffeine, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t carbamazepine, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t diazepam, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t desmethyldiazepam, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t diclofenac, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t naproxen, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t piroxicam, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t digoxin, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t ethanol, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t contraceptive, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t levonorgestrel, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t ethinyl estradiol, ENTITY ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t metoprolol, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t nifedipine, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t phenytoin, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t warfarin, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t midazolam, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t clarithromycin, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t metronidazole, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t pantoprazole, ENTITY \t amoxicillin, ENTITY \n",
      "Sentences: \n",
      "\tBased on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel / ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin . \n",
      "\t Based on ENTITY ENTITY possible ENTITY of ENTITY with other ENTITY , ENTITY adjustment is needed with ENTITY use of the following : ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY ( and its ENTITY , ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , an ENTITY ( ENTITY / ENTITY ENTITY ) , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , ENTITY , or ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t pantoprazole, ENTITY \t warfarin, ENTITY \n",
      "Sentences: \n",
      "\tThere have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors , including pantoprazole , and warfarin concomitantly . \n",
      "\t There have been ENTITY of ENTITY ENTITY and ENTITY in ENTITY receiving ENTITY , including ENTITY , and ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t tetracyclines, ENTITY \t antacids, ENTITY \n",
      "Sentences: \n",
      "\tAbsorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron -containing preparations . \n",
      "\t ENTITY of ENTITY is ENTITY by ENTITY containing ENTITY , ENTITY or ENTITY , and ENTITY -containing ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t carbamazepine, ENTITY \t ondansetron, ENTITY \n",
      "Sentences: \n",
      "\tPhenytoin , Carbamazepine , and Rifampicin : In patients treated with potent inducers of CYP3A4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased . \n",
      "\t ENTITY , ENTITY , and ENTITY : In ENTITY ENTITY potent ENTITY of ENTITY ( i.e. , ENTITY , ENTITY , and ENTITY ) , the ENTITY of ENTITY was significantly ENTITY and ENTITY ENTITY were ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, int \n",
      "Entities: \t lenalidomide, ENTITY \t CCI-779, ENTITY \n",
      "Sentences: \n",
      "\tPhase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma : evidence for lenalidomide - CCI-779 interaction via P - glycoprotein . \n",
      "\t ENTITY of ENTITY and ENTITY in ENTITY with ENTITY : ENTITY for ENTITY - ENTITY ENTITY via ENTITY - ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, int \n",
      "Entities: \t lenalidomide, ENTITY \t CCI-779, ENTITY \n",
      "Sentences: \n",
      "\tThe preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM . \n",
      "\t The ENTITY ENTITY of ENTITY with the ENTITY ENTITY has displayed ENTITY ENTITY and represents a novel ENTITY in ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t dacarbazine, ENTITY \t imexon, ENTITY \n",
      "Sentences: \n",
      "\tInteraction of dacarbazine and imexon , in vitro and in vivo , in human A375 melanoma cells . \n",
      "\t ENTITY of ENTITY and ENTITY , ENTITY and ENTITY , in ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t Imexon, ENTITY \t dacarbazine, ENTITY \n",
      "Sentences: \n",
      "\tImexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells . \n",
      "\t ENTITY and ENTITY show ENTITY ENTITY but not ENTITY in ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t warfarin, ENTITY \t warfarin, ENTITY \n",
      "Sentences: \n",
      "\tIn total , 430,455 warfarin users contributed 407,370 person - years of warfarin use . \n",
      "\t In total , 430,455 ENTITY ENTITY contributed 407,370 ENTITY - ENTITY of ENTITY use .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t dexmedetomidine, ENTITY \t analgesic, ENTITY \n",
      "Sentences: \n",
      "\tWe concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation , which limits the use of dexmedetomidine as an analgesic in humans . \n",
      "\t We concluded that the ENTITY ENTITY of ENTITY with ENTITY may have beneficial effects in the ENTITY of ENTITY without causing ENTITY , which limits the use of ENTITY as an ENTITY in ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t quinpirole, ENTITY \t amphetamine, ENTITY \n",
      "Sentences: \n",
      "\tIn female rats , neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole -free controls sensitized to amphetamine . \n",
      "\t In ENTITY ENTITY , ENTITY ENTITY ENTITY ENTITY ENTITY ENTITY ENTITY with ENTITY -free ENTITY ENTITY to ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t amphetamine, ENTITY \t quinpirole, ENTITY \n",
      "Sentences: \n",
      "\tIn female rats , neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole -free controls sensitized to amphetamine . \n",
      "\t In ENTITY ENTITY , ENTITY ENTITY ENTITY ENTITY ENTITY ENTITY ENTITY with ENTITY -free ENTITY ENTITY to ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t quinpirole, ENTITY \t quinpirole, ENTITY \n",
      "Sentences: \n",
      "\tRats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug - paired context compared with saline - treated controls . \n",
      "\t ENTITY ENTITY ENTITY ENTITY enhanced time spent in the ENTITY -paired ENTITY compared with ENTITY -free ENTITY ENTITY with ENTITY , but only ENTITY ENTITY with ENTITY spent more time in the ENTITY - ENTITY ENTITY ENTITY with ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t quinpirole, ENTITY \t amphetamine, ENTITY \n",
      "Sentences: \n",
      "\tRats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug - paired context compared with saline - treated controls . \n",
      "\t ENTITY ENTITY ENTITY ENTITY enhanced time spent in the ENTITY -paired ENTITY compared with ENTITY -free ENTITY ENTITY with ENTITY , but only ENTITY ENTITY with ENTITY spent more time in the ENTITY - ENTITY ENTITY ENTITY with ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t quinpirole, ENTITY \t amphetamine, ENTITY \n",
      "Sentences: \n",
      "\tRats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug - paired context compared with saline - treated controls . \n",
      "\t ENTITY ENTITY ENTITY ENTITY enhanced time spent in the ENTITY -paired ENTITY compared with ENTITY -free ENTITY ENTITY with ENTITY , but only ENTITY ENTITY with ENTITY spent more time in the ENTITY - ENTITY ENTITY ENTITY with ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t amphetamine, ENTITY \t amphetamine, ENTITY \n",
      "Sentences: \n",
      "\tRats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug - paired context compared with saline - treated controls . \n",
      "\t ENTITY ENTITY ENTITY ENTITY enhanced time spent in the ENTITY -paired ENTITY compared with ENTITY -free ENTITY ENTITY with ENTITY , but only ENTITY ENTITY with ENTITY spent more time in the ENTITY - ENTITY ENTITY ENTITY with ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t quinpirole, ENTITY \t amphetamine, ENTITY \n",
      "Sentences: \n",
      "\tRats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug - paired context compared with saline - treated controls . \n",
      "\t ENTITY ENTITY ENTITY ENTITY enhanced time spent in the ENTITY -paired ENTITY compared with ENTITY -free ENTITY ENTITY with ENTITY , but only ENTITY ENTITY with ENTITY spent more time in the ENTITY - ENTITY ENTITY ENTITY with ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t quinpirole, ENTITY \t amphetamine, ENTITY \n",
      "Sentences: \n",
      "\tRats treated with neonatal quinpirole enhanced time spent in the amphetamine -paired context compared with quinpirole -free controls conditioned with amphetamine , but only female controls conditioned with amphetamine spent more time in the drug - paired context compared with saline - treated controls . \n",
      "\t ENTITY ENTITY ENTITY ENTITY enhanced time spent in the ENTITY -paired ENTITY compared with ENTITY -free ENTITY ENTITY with ENTITY , but only ENTITY ENTITY with ENTITY spent more time in the ENTITY - ENTITY ENTITY ENTITY with ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Moxifloxacin, ENTITY \t sucralfate, ENTITY \n",
      "Sentences: \n",
      "\tMoxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi - minerals in neutral media . \n",
      "\t ENTITY and ENTITY reacts faster with ENTITY and ENTITY in ENTITY whereas with ENTITY in basic media and ENTITY - ENTITY in ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Lomefloxacin, ENTITY \t sucralfate, ENTITY \n",
      "Sentences: \n",
      "\tMoxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi - minerals in neutral media . \n",
      "\t ENTITY and ENTITY reacts faster with ENTITY and ENTITY in ENTITY whereas with ENTITY in basic media and ENTITY - ENTITY in ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t Implanon, ENTITY \t antiretroviral, ENTITY \n",
      "Sentences: \n",
      "\tImplanon failure in an HIV - positive woman on antiretroviral therapy resulting in two ectopic pregnancies . \n",
      "\t ENTITY in an ENTITY - ENTITY ENTITY on ENTITY resulting in two ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, advise \n",
      "Entities: \t antiretroviral, ENTITY \t Implanon, ENTITY \n",
      "Sentences: \n",
      "\tWe present an interesting case of an HIV - positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place . \n",
      "\t We present an interesting ENTITY of an ENTITY - ENTITY ENTITY on ENTITY having ENTITY on two separate ENTITY with ENTITY in place .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, mechanism \n",
      "Entities: \t CRM197, ENTITY \t doxorubicin, ENTITY \n",
      "Sentences: \n",
      "\tCRM197 induced apoptosis , and furthermore , the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T - ALL cell line . \n",
      "\t ENTITY ENTITY ENTITY , and furthermore , the combination of ENTITY plus ENTITY enhanced ENTITY in a ENTITY - ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Furafylline, ENTITY \t sulfaphenazole, ENTITY \n",
      "Sentences: \n",
      "\tFurafylline and sulfaphenazole had no effect , while quinidine appeared to augment precocene I toxicity . \n",
      "\t ENTITY and ENTITY had ENTITY , while ENTITY appeared to augment ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t Furafylline, ENTITY \t precocene I, ENTITY \n",
      "Sentences: \n",
      "\tFurafylline and sulfaphenazole had no effect , while quinidine appeared to augment precocene I toxicity . \n",
      "\t ENTITY and ENTITY had ENTITY , while ENTITY appeared to augment ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t sulfaphenazole, ENTITY \t precocene I, ENTITY \n",
      "Sentences: \n",
      "\tFurafylline and sulfaphenazole had no effect , while quinidine appeared to augment precocene I toxicity . \n",
      "\t ENTITY and ENTITY had ENTITY , while ENTITY appeared to augment ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t omeprazole, ENTITY \t clopidogrel, ENTITY \n",
      "Sentences: \n",
      "\tConcomitant use of omeprazole and clopidogrel was found to decrease the exposure ( AUC ) to clopidogrel 's active metabolite by 50 % and to sharply increase platelet reactivity , as a result of inhibition by omeprazole of CYP2C19 , a cytochrome P450 ( CYP ) enzyme . \n",
      "\t ENTITY ENTITY ENTITY and ENTITY was found to ENTITY the ENTITY ( ENTITY ) to ENTITY ENTITY by 50 % and to sharply ENTITY ENTITY , as a result of ENTITY by ENTITY of ENTITY , a ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Pantoprazole, ENTITY \t clopidogrel, ENTITY \n",
      "Sentences: \n",
      "\tPantoprazole has a much weaker effect on clopidogrel 's pharmacokinetics and on platelet reactivity during concomitant use . \n",
      "\t ENTITY has a much weaker ENTITY on ENTITY ENTITY and on ENTITY during ENTITY use .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t omeprazole, ENTITY \t esomeprazole, ENTITY \n",
      "Sentences: \n",
      "\tRegulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided . \n",
      "\t ENTITY that the ENTITY of ENTITY and the ENTITY ENTITY and ENTITY should be avoided .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t docetaxel, ENTITY \t sunitinib, ENTITY \n",
      "Sentences: \n",
      "\tSunitinib as a single agent exhibits anti - proliferative effects in vitro in NSCLC cell lines with EGFR T790 M and K - ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration . \n",
      "\t ENTITY as a ENTITY exhibits ENTITY - ENTITY ENTITY ENTITY in ENTITY ENTITY with ENTITY ENTITY and ENTITY - ENTITY ENTITY but the sequential ENTITY of ENTITY followed by ENTITY is superior to ENTITY followed by ENTITY and ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t celecoxib, ENTITY \t celecoxib, ENTITY \n",
      "Sentences: \n",
      "\tWe found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells . \n",
      "\t We found ENTITY between ENTITY and the four ENTITY in the ENTITY ENTITY following all ENTITY and between ENTITY and ENTITY in all ENTITY except for two ENTITY in ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t celecoxib, ENTITY \t doxorubicin, ENTITY \n",
      "Sentences: \n",
      "\tWe found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells . \n",
      "\t We found ENTITY between ENTITY and the four ENTITY in the ENTITY ENTITY following all ENTITY and between ENTITY and ENTITY in all ENTITY except for two ENTITY in ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t acetyl - l - carnitine, ENTITY - ENTITY - ENTITY \t alpha - lipoic acid, ENTITY - ENTITY \n",
      "Sentences: \n",
      "\t( ii ) acetyl - l - carnitine elicits a significant protective effect on DEB induced toxicity , which was potentiated by alpha - lipoic acid . \n",
      "\t ( ii ) ENTITY - ENTITY - ENTITY elicits a significant ENTITY on ENTITY ENTITY ENTITY , which was ENTITY by ENTITY - ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ketamine, ENTITY \t propofol, ENTITY \n",
      "Sentences: \n",
      "\tWe retrospectively reviewed the records of 7 pediatric oncology patients who received low - dose ketamine in conjunction with propofol for total intravenous anesthesia ( TIVA ) repeatedly for radiation therapy . \n",
      "\t We ENTITY ENTITY the ENTITY of 7 ENTITY ENTITY who received ENTITY - ENTITY ENTITY in ENTITY with ENTITY for ENTITY ( ENTITY ) repeatedly for ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, effect \n",
      "Entities: \t ketamine, ENTITY \t propofol, ENTITY \n",
      "Sentences: \n",
      "\tBased on this experience , we suggest that low - dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA . \n",
      "\t Based on this ENTITY , we suggest that ENTITY - ENTITY ENTITY added to ENTITY may be ENTITY ENTITY of ENTITY in ENTITY with a ENTITY of ENTITY with ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t S - ketamine, ENTITY - ENTITY \t ticlopidine, ENTITY \n",
      "Sentences: \n",
      "\tIn this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg / kg S - ketamine after pretreatments with oral ticlopidine ( 250 mg twice daily ) , itraconazole ( 200 mg once daily ) , or placebo in 6-day treatment periods at intervals of 4 weeks . \n",
      "\t In this ENTITY , ENTITY , ENTITY , 11 ENTITY ENTITY 0.2 mg / kg ENTITY - ENTITY after ENTITY with ENTITY ( 250 mg twice daily ) , ENTITY ( 200 mg once ENTITY ) , or ENTITY in 6-day ENTITY periods at ENTITY of 4 ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t S - ketamine, ENTITY - ENTITY \t itraconazole, ENTITY \n",
      "Sentences: \n",
      "\tIn this randomized , blinded , crossover study , 11 healthy volunteers ingested 0.2 mg / kg S - ketamine after pretreatments with oral ticlopidine ( 250 mg twice daily ) , itraconazole ( 200 mg once daily ) , or placebo in 6-day treatment periods at intervals of 4 weeks . \n",
      "\t In this ENTITY , ENTITY , ENTITY , 11 ENTITY ENTITY 0.2 mg / kg ENTITY - ENTITY after ENTITY with ENTITY ( 250 mg twice daily ) , ENTITY ( 200 mg once ENTITY ) , or ENTITY in 6-day ENTITY periods at ENTITY of 4 ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t Ticlopidine, ENTITY \t ketamine, ENTITY \n",
      "Sentences: \n",
      "\tTiclopidine treatment increased the mean area under the plasma concentration - time curve extrapolated to infinity ( AUC(0- ) ) of oral ketamine by 2.4-fold , whereas itraconazole treatment did not increase the exposure to S - ketamine . \n",
      "\t ENTITY ENTITY ENTITY the ENTITY under the ENTITY ENTITY - ENTITY extrapolated to ENTITY ( AUC(0- ) ) of ENTITY ENTITY by 2.4-fold , whereas ENTITY ENTITY did not ENTITY the ENTITY ENTITY - ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, mechanism \n",
      "Entities: \t ticlopidine, ENTITY \t itraconazole, ENTITY \n",
      "Sentences: \n",
      "\tIn the ticlopidine and itraconazole phases , the areas under the effect - time curves ( self - reported drowsiness and performance ) were significantly higher than those in the placebo phase ( P < 0.05 ) . \n",
      "\t In the ENTITY and ENTITY ENTITY , the areas under the ENTITY - ENTITY ( ENTITY - ENTITY ENTITY and ENTITY ) were ENTITY than those in the ENTITY ( P < 0.05 ) .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t ABT-737, ENTITY \t DZNep, ENTITY \n",
      "Sentences: \n",
      "\tIn addition , DZNep insensitivity might be associated with overexpression of Bcl-2 , and the combination of ABT-737 and DZNep could synergistically induced apoptosis . \n",
      "\t In addition , ENTITY ENTITY might be ENTITY ENTITY of ENTITY , and the ENTITY of ENTITY and ENTITY could ENTITY ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t methylglyoxal, ENTITY \t piperacillin, ENTITY \n",
      "Sentences: \n",
      "\tDistinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects . \n",
      "\t ENTITY and ENTITY ENTITY was observed between ENTITY and ENTITY by ENTITY when compared with their ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t dasatinib, ENTITY \t paclitaxel, ENTITY \n",
      "Sentences: \n",
      "\tHEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone . \n",
      "\t ENTITY ENTITY ENTITY plus ENTITY formed fewer ENTITY than did ENTITY ENTITY either ENTITY alone .\n",
      "\n",
      "\n",
      "Predicted Relation: \t effect, none \n",
      "Entities: \t dasatinib, ENTITY \t paclitaxel, ENTITY \n",
      "Sentences: \n",
      "\tStudies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib -mediated induction of p27(Kip1 ) enhanced paclitaxel -induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression . \n",
      "\t ENTITY with ENTITY and ENTITY ENTITY of ENTITY and ENTITY suggest that ENTITY -mediated ENTITY of ENTITY ) ENTITY ENTITY -induced ENTITY by negatively regulating ENTITY and ENTITY ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t tamoxifen, ENTITY \t SSRI antidepressants, ENTITY ENTITY \n",
      "Sentences: \n",
      "\tIt is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially SSRI antidepressants such as paroxetine and fluoxetine . \n",
      "\t It is better to avoid ENTITY ENTITY to ENTITY ENTITY ENTITY for ENTITY , especially ENTITY ENTITY such as ENTITY and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t tamoxifen, ENTITY \t paroxetine, ENTITY \n",
      "Sentences: \n",
      "\tIt is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially SSRI antidepressants such as paroxetine and fluoxetine . \n",
      "\t It is better to avoid ENTITY ENTITY to ENTITY ENTITY ENTITY for ENTITY , especially ENTITY ENTITY such as ENTITY and ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t tamoxifen, ENTITY \t fluoxetine, ENTITY \n",
      "Sentences: \n",
      "\tIt is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer , especially SSRI antidepressants such as paroxetine and fluoxetine . \n",
      "\t It is better to avoid ENTITY ENTITY to ENTITY ENTITY ENTITY for ENTITY , especially ENTITY ENTITY such as ENTITY and ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t advise, none \n",
      "Entities: \t antidepressant, ENTITY \t tamoxifen, ENTITY \n",
      "Sentences: \n",
      "\tIf in certain cases , an antidepressant is considered necessary , it may be advisable to replace tamoxifen with anastrozole . \n",
      "\t If in certain ENTITY , an ENTITY is considered necessary , it may be advisable to replace ENTITY with ENTITY .\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t calcium, ENTITY \t nonheme ( as sulfate ) and heme ( as CRBC ) iron, ENTITY ( as ENTITY ) and ENTITY ( as ENTITY ) ENTITY \n",
      "Sentences: \n",
      "\tIn conclusion , we demonstrated an isolated effect of calcium ( as chloride ) on absorption of 5 mg of iron provided as nonheme ( as sulfate ) and heme ( as CRBC ) iron . \n",
      "\t In conclusion , we demonstrated an ENTITY ENTITY of ENTITY ( as ENTITY ) on ENTITY of 5 mg of ENTITY provided as ENTITY ( as ENTITY ) and ENTITY ( as ENTITY ) ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t mechanism, none \n",
      "Entities: \t calcium, ENTITY \t heme ( as CRBC ) iron, ENTITY ( as ENTITY ) ENTITY \n",
      "Sentences: \n",
      "\tIn conclusion , we demonstrated an isolated effect of calcium ( as chloride ) on absorption of 5 mg of iron provided as nonheme ( as sulfate ) and heme ( as CRBC ) iron . \n",
      "\t In conclusion , we demonstrated an ENTITY ENTITY of ENTITY ( as ENTITY ) on ENTITY of 5 mg of ENTITY provided as ENTITY ( as ENTITY ) and ENTITY ( as ENTITY ) ENTITY\n",
      "\n",
      "\n",
      "Predicted Relation: \t none, advise \n",
      "Entities: \t nonheme ( as sulfate ) and heme ( as CRBC ) iron, ENTITY ( as ENTITY ) and ENTITY ( as ENTITY ) ENTITY \t heme ( as CRBC ) iron, ENTITY ( as ENTITY ) ENTITY \n",
      "Sentences: \n",
      "\tIn conclusion , we demonstrated an isolated effect of calcium ( as chloride ) on absorption of 5 mg of iron provided as nonheme ( as sulfate ) and heme ( as CRBC ) iron . \n",
      "\t In conclusion , we demonstrated an ENTITY ENTITY of ENTITY ( as ENTITY ) on ENTITY of 5 mg of ENTITY provided as ENTITY ( as ENTITY ) and ENTITY ( as ENTITY ) ENTITY\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print('We print the baseline first and then the ner blinded version. Gold relation corresponds to baseline\\n\\n')\n",
    "curr_linenum = 0\n",
    "with open(original_sentences_path) as original_sentences, open(ner_blinding_sentences_path) as ner_blinding_sentences:\n",
    "    for x, y in zip(original_sentences, ner_blinding_sentences):\n",
    "        needed_linenums = list(needed_linenum_and_relation.keys())\n",
    "        if curr_linenum in needed_linenums:\n",
    "            _, e1_b, e2_b, s_b = read_sentence_and_entities(x.strip())\n",
    "            _, e1_c, e2_c, s_c = read_sentence_and_entities(y.strip())\n",
    "            r_b, r_c = needed_linenum_and_relation[curr_linenum]\n",
    "            entities_blinded_per_sentence.append(s_c.split().count('ENTITY'))\n",
    "            if r_b == 'int': interaction += 1\n",
    "            elif r_b == 'mechanism': mechanism += 1\n",
    "            elif r_b == 'advise': advice += 1\n",
    "            elif r_b == 'effect': effect += 1\n",
    "            elif r_b == 'none': none += 1\n",
    "            print('Predicted Relation: \\t {0}, {1} \\nEntities: \\t {2}, {3} \\t {4}, {5} \\nSentences: \\n\\t{6} \\n\\t {7}'.format(\n",
    "                    r_b, r_c, e1_b, e1_c, e2_b, e2_c, s_b, s_c))\n",
    "            print('\\n')\n",
    "        curr_linenum += 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2 73 19 62 155\n"
     ]
    }
   ],
   "source": [
    "print(interaction, mechanism, advice, effect, none)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "311"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "interaction + mechanism + advice + effect + none"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(14.237942122186496, 41, 4, 8.165568107458933, 12.0)"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "(np.mean(entities_blinded_per_sentence), np.max(entities_blinded_per_sentence), np.min(entities_blinded_per_sentence),\n",
    "np.std(entities_blinded_per_sentence), np.median(entities_blinded_per_sentence))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "num_sentences_where_entities_blinded = 0 # count the number of sentences where the numbers were blinded\n",
    "for numbers in entities_blinded_per_sentence:\n",
    "    if numbers > 0:\n",
    "        num_sentences_where_entities_blinded += 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "311"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "num_sentences_where_entities_blinded"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
